GSK forges $12 billion alliance with Hengrui Pharma
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Subscribe To Our Newsletter & Stay Updated